Post Profile

Improving participation in cancer screening should be a priority

(European Society for Medical Oncology) Early diagnosis of cancer is linked to better survival rates. Unfortunately, participation rates for cancer screening worldwide are low even when screening programs are free. The ESMO 2016 Congress is showcasing five studies on this important area of cancer management which look at alternative ways to overcome barriers and improve screening rates.
read more


Related Posts

Merck KGaA: Erbitux - First Treatment In 30 Years To Prolong Survival In 1st-Line Recurrent And/Or Metastatic Head And Neck Cancer

Health : Medical News Today

Data presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm demonstrate that the addition of Erbitux® (cetuximab) to platinum-based chemotherapy increases overall survival (OS) compared to chemother...

The landscape of medical oncology in Europe by 2020

Health : Medical News Today

Many large European countries may be facing a future shortage of medical oncologists without realizing it--a situation that could have dire consequences for cancer patients, the European Society for Medical Oncology (ESMO) has warne...

More research urged to compare and validate genomic tests for patients with early breast cancer

Health : Medical News Today

The European Society for Medical Oncology (ESMO) has welcomed preliminary clinical trial results that suggest genomic testing could allow many patients with early breast cancer to safely avoid chemotherapy. The new trial results[1],...

Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.


Copyright © 2016 Regator, LLC